Panitumumab
| Panitumumab?
| |
| Therapeutic monoclonal antibody | |
| Source | Human recombinant |
| Target | EGFR |
| Identifiers | |
| CAS number | |
| ATC code | L01 |
| PubChem | ? |
| Chemical data | |
| Formula | C6306H9732N1672O1994S46 |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ∼7.5 days (range: 4-11 days) |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
℞ Prescription only |
| Routes | intravenous |
|
WikiDoc Resources for Panitumumab | |
|
Articles | |
|---|---|
|
Most recent articles on Panitumumab Most cited articles on Panitumumab | |
|
Media | |
|
Powerpoint slides on Panitumumab | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Panitumumab at Clinical Trials.gov Clinical Trials on Panitumumab at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Panitumumab
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Panitumumab Discussion groups on Panitumumab Patient Handouts on Panitumumab Directions to Hospitals Treating Panitumumab Risk calculators and risk factors for Panitumumab
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Panitumumab | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Overview
Panitumumab (ABX-EGF) is a fully human monoclonal antibody specific to the EGF receptor (see illustration)[2]. It was FDA approved for the first time in September 2006, for the "the treatment of EGFR-expressing metastatic colorectal cancer with disease progression" despite prior treatment [1]. Panitumumab is manufactured by Amgen and marketed as Vectibix in the USA.
The compound works by binding to the extracellular domain of the EGFR (epidermal growth factor receptor) preventing its activation. This in turn, results in halting of the cascade of intracellular signals dependent on this receptor. [2]
Panitumumab is produced by immunization of transgenic mice (xenomouse), that are able to produce human immunoglobulin light and heavy chains. After immunization of these animals a specific clone of B cells that produced an antibody against EGFR was selected and immortalized in Chinese hamster ovary (CHO) cells. These cells are then used for the full scale manufacture of the antibody.
Although they both target the EGFR, panitumumab (IgG2) and cetuximab (IgG1) differ in their isotype and they might differ in their mechanism of action. Monoclonal antibodies of the IgG1 isotype may activate the complement pathway and mediate ADCC (antibody-dependent cellular cytotoxicity) better than their IgG2 counterparts, hence although they have not been documented, differences in the responses in treatments with these two antibodies might be expected. [3]
References
Further readings
Philippe Rougier, Emmanuel Mitry, Sophie Dominguez. Les Cancers Digestifs ; Springer , September 1, 2006, page=291 ; language=French
Human monoclonal antibodies ("-u-") | |
|---|---|
| "-limu-" (immune system) | immunosuppression: Adalimumab, Atorolimumab, Gantenerumab, Golimumab, Lerdelimumab, Metelimumab, Morolimumab, Ziralimumab
immune activation: Ipilimumab, Tremelimumab other: Bertilimumab |
| "-kinu-" (interleukin as target) | Canakinumab |
| "-tumu-" (cancer immunotherapy) | Adecatumumab, Anetumumab, Belimumab, Duntumumab, Iratumumab, Lexatumumab, Lucatumumab, Mapatumumab, Ofatumumab, Panitumumab, Pritumumab, Votumumab, Zalutumumab, Zanolimumab |
| "-osu-" (bone) | Denosumab |
| "-mulu-" (musculoskeletal) | Durimulumab, Durmulumab, Stamulumab |
| "-fungu-" (fungal) | Efungumab |
| "-viru-" (viral) | Exbivirumab, Libivirumab, Regavirumab, Sevirumab, Tuvirumab |
| "-bacu-" (bacterial) | Nebacumab, Raxibacumab |
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
